<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735303</url>
  </required_header>
  <id_info>
    <org_study_id>DRGS-4-2018</org_study_id>
    <nct_id>NCT03735303</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D3 and Omega-3FA on Leptin and HbA1C With Vitamin D Deficiency</brief_title>
  <official_title>The Combined Effect of Vitamin D3 and Omega-3 Supplements on Serum Leptin and Glycated Hemoglobin (Hb A1C) Levels in Jordanian People With Vitamin D Deficiency.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Science Private University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Science Private University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Combined effect of Vitamin D3 and Omega-3 supplements on serum leptin and Glycated
      hemoglobin (Hb A1C) levels in Jordanian people with vitamin D deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nothing is published in the literature about effect of vitamin D3 (VD3) and omega-3 fatty
      acids (omega-3FA) on serum leptin and glycated hemoglobin ( HbA1C)

      This study will be conducted to investigate effect of VD3 and omega-3FA alone and with each
      other on serum leptin and Glycated hemoglobin (Hb A1C) levels in Jordanian people with
      vitamin D deficiency.

      This randomized, controlled clinical trial will be designed to test effects of 50,000 IU VD3
      weekly and 1000 mg omega-3FA daily for eight weeks, separately and with each other, on on
      serum leptin and Glycated hemoglobin (Hb A1C) levels .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VD 3</measure>
    <time_frame>8 weeks</time_frame>
    <description>Serum level of 25-hydroxyvitamin D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>leptin</measure>
    <time_frame>8 weeks</time_frame>
    <description>serum level of leptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1C</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma concentration of HbA1C</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>VD3 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omega 3- FA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VD3 and omega 3 FA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>no intervention was given</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VD3 group</intervention_name>
    <description>VD3 50000 IU/ week for 8 weeks</description>
    <arm_group_label>VD3 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega 3 FA group</intervention_name>
    <description>omega 3 FA group 300 mg once daily for 8 weeks</description>
    <arm_group_label>omega 3- FA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VD3 and omega- 3FA group</intervention_name>
    <description>50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks</description>
    <arm_group_label>VD3 and omega 3 FA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>no intervention was given</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  jordanian people aged 25-55

          -  medical diagnosis of vitamin D deficiency ( VD &lt;25 ng/ ml)

        Exclusion Criteria:

          -  Blood disorders including

          -  thalassemia

          -  sickle cell disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud S Abu-Samak, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Applied Science Private University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Applied Science University</name>
      <address>
        <city>Amman</city>
        <zip>11931</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <results_reference>
    <citation>Ross AC. The 2011 report on dietary reference intakes for calcium and vitamin D. Public Health Nutr. 2011 May;14(5):938-9. doi: 10.1017/S1368980011000565.</citation>
    <PMID>21492489</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin D3</keyword>
  <keyword>vitamin D deficiency</keyword>
  <keyword>leptin</keyword>
  <keyword>A1C</keyword>
  <keyword>omega-3 fatty acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underline results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>when summary data will published</ipd_time_frame>
    <ipd_access_criteria>open access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

